Cargando…
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
BACKGROUND: The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) evaluated rivaroxaban (20/15 mg/d) versus warfarin in patients with atrial fibrillation. A separate trial, J‐ROCKE...
Autores principales: | Chan, Yi‐Hsin, Lee, Hsin‐Fu, Wang, Chun‐Li, Chang, Shang‐Hung, Yeh, Chih‐Hsin, Chao, Tze‐Fan, Yeh, Yung‐Hsin, Chen, Shih‐Ann, Kuo, Chi‐Tai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898830/ https://www.ncbi.nlm.nih.gov/pubmed/31623498 http://dx.doi.org/10.1161/JAHA.119.013053 |
Ejemplares similares
-
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016) -
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015) -
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017) -
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
por: Ugowe, Francis E., et al.
Publicado: (2021) -
Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)